BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 30649751)

  • 1. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
    Curigliano G; Shah RR
    Drug Saf; 2019 Feb; 42(2):247-262. PubMed ID: 30649751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of adverse events associated with idelalisib treatment: expert panel opinion.
    Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
    Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
    Greenwell IB; Flowers CR; Blum KA; Cohen JB
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
    Wang X; Ding J; Meng LH
    Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
    Greenwell IB; Ip A; Cohen JB
    Oncology (Williston Park); 2017 Nov; 31(11):821-8. PubMed ID: 29179250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
    Fruman DA; Rommel C
    Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
    Burger JA; Okkenhaug K
    Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
    Hanlon A; Brander DM
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib in the management of lymphoma.
    Cheah CY; Fowler NH
    Blood; 2016 Jul; 128(3):331-6. PubMed ID: 27252232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
    Krause G; Hassenrück F; Hallek M
    Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PI3 kinase in cancer.
    Bauer TM; Patel MR; Infante JR
    Pharmacol Ther; 2015 Feb; 146():53-60. PubMed ID: 25240910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the PI3K pathway in cancer: are we making headway?
    Janku F; Yap TA; Meric-Bernstam F
    Nat Rev Clin Oncol; 2018 May; 15(5):273-291. PubMed ID: 29508857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
    Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
    J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
    Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
    Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
    Castillo JJ; Furman M; Winer ES
    Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.